Recent Updates — NKGN

On August 5, 2026, NKGen Biotech, Inc. and its subsidiary entered into a Fourth Amendment to their Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited. The Lender extended an additional loan of $1,050,500, which includes a $95,500 facilitation fee, resulting in net proceeds of $955,000 to the Borrowers. This debt is documented by a new promissory note convertible into common stock at $0.08 per share. The Company also issued 13,304,114 consideration shares payable over 30 months and an additional warrant exercisable for three times the loan principal divided by the conversion price, at an exercise price of $0.08 per share. A voting agreement was executed to secure shareholder approval for increasing authorized common stock to accommodate these issuances. NKGen Biotech operates in the biotechnology industry.

NKGen Biotech, Inc. entered into a First Amendment to Equity and Business Loan Agreement with BDW Investments, LLC on July 13, 2026, modifying the terms of a $5 million multi-draw term loan. The amendment replaces the all-assets security agreement with a first priority perfected security interest in specific real estate collateral of the Borrower, and amends the definition of Senior Loan to include the AlpineBrook Capital GP I Limited Senior Convertible Loan Agreement. NKGen Biotech, Inc. is a biotechnology company focused on on-demand, on-site, personalized cell therapy.

NKGen Biotech, Inc. entered into a Third Omnibus Amendment to its Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited, which includes an additional $2,420,000 loan providing net proceeds of $2,200,000. The amendment increases the total consideration shares to 12,953,947 and includes a new promissory note and warrant, both with a conversion or exercise price of $0.08 per share.